Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.55) by 44.52 percent. This is a 75.43 percent increase over losses of $(3.50) per share from the same period last year. The company reported quarterly sales of $3.80 million which missed the analyst consensus estimate of $5.75 million by 33.91 percent.
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.55) by 44.52 percent. This is a 75.43 percent increase over losses of $(3.50) per share from the same period last year. The company reported quarterly sales of $3.80 million which missed the analyst consensus estimate of $5.75 million by 33.91 percent.
Tonix Pharmicals（納斯達克股票代碼：TNXP）公佈的季度虧損爲每股0.86美元，比分析師普遍預期的1.55美元（1.55美元）高出44.52％。與去年同期每股虧損3.50美元（3.50）相比，增長了75.43％。該公司公佈的季度銷售額爲380萬美元，比分析師普遍預期的575萬美元低33.91％。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧